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Markov modelObjectives: Today, hospitals and other health care-related institutions are accumulating a growing bulk of
real world clinical data. Such data offer new possibilities for the generation of disease models for the
health economic evaluation. In this article, we propose a new approach to leverage cancer registry data
for the development of Markov models. Records of breast cancer patients from a clinical cancer registry
were used to construct a real world data driven disease model.
Methods: We describe a model generation process which maps database structures to disease state def-
initions based on medical expert knowledge. Software was programmed in Java to automatically derive a
model structure and transition probabilities. We illustrate our method with the reconstruction of a pub-
lished breast cancer reference model derived primarily from clinical study data. In doing so, we exported
longitudinal patient data from a clinical cancer registry covering eight years. The patient cohort (n = 892)
comprised HER2-positive and HER2-negative women treated with or without Trastuzumab.
Results: The models generated with this method for the respective patient cohorts were comparable to
the reference model in their structure and treatment effects. However, our computed disease models
reflect a more detailed picture of the transition probabilities, especially for disease free survival and
recurrence.
Conclusions: Our work presents an approach to extract Markov models semi-automatically using real
world data from a clinical cancer registry. Health care decision makers may benefit from more realistic
disease models to improve health care-related planning and actions based on their own data.
 2016 The Authors. Published by Elsevier Inc. This is an openaccess article under the CCBY license (http://
creativecommons.org/licenses/by/4.0/).1. Introduction
Breast cancer is the most leading cause of cancer death in
women worldwide. More than one million patients are diagnosed
with breast cancer every year [1]. In the last decades, targeted ther-
apies for HER2 (human epidermal growth factor receptor 2)-
positive cancer were developed to improve the prognosis for these
patients. HER2 is a transmembrane receptor tyrosine kinase
expressed in epithelial cells as found in breast tissue. Overexpres-
sion of the HER2 protein or amplification on the HER2 gene occurs
in about 15–25% of all breast cancer cases [2]. Both indicate aggres-
sive growth and spreading of the tumor. Several health economics
evaluations assessed the cost-utility and cost-effectiveness of Tras-tuzumab, a humanized monoclonal antibody, in the treatment of
HER2-positive women [3–6].
In health economics, disease models (DM) are widely used to
conduct evaluations of new treatment plans, medications or pre-
vention programs [7]. Health care facilities use an increasing num-
ber of information systems to document the treatment of patients.
However, these systems also collect data for ‘‘such activities as
analysis, research, quality and safety measurement, public health,
payment, provider certification or accreditation, marketing, and
other business applications, including strictly commercial activi-
ties” [8]. This approach is referred to as secondary use of data, i.e.,
data are re-used in a different context. It is general consensus that
such clinical data have ‘‘significant potential to facilitate research,
improve quality of care for individuals and populations, and reduce
healthcare costs” [9]. Before secondary use can tap its full potential
issues like data stewardship principles, reduction and elimination
of data silos and guaranteed patient privacy must be addressed [9].
Several US [10] and European [11] research initiatives also from
scientific societies such as ISPOR (International Society for Pharma-
coeconomics and Outcomes Research) focus on the usage of ‘‘real
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vices research [12,13]. These initiatives demand for real world data
to assess the impact of new medical interventions in routine care
settings. Especially in disease modeling, an increased usage of real
world data could bridge the gap between efficacy and effective-
ness, i.e., the relation of cost to (added) value under routine condi-
tions [14].
This article presents a 4-step model generation process (Defini-
tion – Selection – Transformation – Generation) to derive a Markov
model from a cancer registry in a semi-automatic manner. We
illustrate our approach in a validation study by re-constructing a
previously published DM by Blank et al. [3] with data from routine
care.
We demonstrate how inclusion and exclusion criteria from the
randomized Herceptin Adjuvant Trial (HERA) are used to select a
suitable cohort of patients [15]. Moreover, definitions of disease
states are mapped to database tables from a tumor documentation
system. To assess differences between the results obtained from
real world data and data collected under optimal conditions of a
randomized clinical trial (RCT), transition probabilities of the com-
puted model are compared with probabilities derived from a breast
cancer RCT.2. Background
In general, the structure of a Markov DM consists of disease
states and transitions. Typically, the probabilities of these transi-
tions should be derived from the most representative data sources,
e.g., population-based epidemiological studies, systematic-
reviews, or meta-analyses. If none of the above are available, RCTs
are being used regularly [16].
A DM based on patient records captured in a large clinical data-
base instead of RCTs could improve DMs to better reflect the clin-
ical reality. That means the efficacy of interventions can be
confirmed with data from clinical routine conditions [17]. Health
care decision makers could improve the development and alloca-
tion of measures to the health care system based on more realistic
forecasts [12]. As a consequence, hospitals and disease registries
should not use their data for the single purpose of patient care
but to ‘‘dig for hidden gold” and ‘‘uncover the treasures buried in
hospital medical records” [18]. This could lead to continuous
improvement in health and health care what is commonly referred
to as ‘‘the learning health system” [19]. The approach presented in
this work supports this paradigm as it makes use of a real world,
health care data collection.3. Materials and methods
In health economics, the most common model types are deci-
sion trees and Markov models [20]. Our study concentrates not
on decision trees but on Markov models because these can handle
more complex and time-depending scenarios. The structure of a
Markov model consists of S = {s1, s2, . . ., sn} disease states and a
maximum of n2 transitions between them. States are specified as
mutually exclusive, i.e., every patient is only allocated to clearly
distinctive disease conditions (‘‘no overlaps”). Moreover, the states
are collectively exhaustive, i.e., the complete disease history is
illustrated in the model structure (‘‘no gaps”). While passing
through the model every patient can be allocated to only one par-
ticular disease state at any given point in time. In health economic
modeling every state is assigned with specific costs and utility val-
ues, e.g., quality of life. Cohort simulations are performed to cap-
ture all costs and utilities for a cohort of patients which is
distributed across all the states during the desired time horizon
H [16]. While passing through the different states of the DM thecohort collects costs and utilities. These values can be summed
up for further analysis, e.g., cost-effectiveness evaluation.
3.1. Cancer registry
The clinical cancer registry of the Cancer Center (CC) Heilbronn-
Franken is operated by the SLK-Hospital Holding, located in south-
ern Germany. Its enrollment population amounts to about 1million
people. In the region of Heilbronn-Franken, the SLK-Hospital
Holding is the largest hospital owner. This implies that most cancer
cases in the administrative district are treated there [21].
Documentation in the CC started in 1986. Today, the database
comprises about 60,000 cases. Since 2001, the Giessen Tumor
Documentation System (GTDS) [22] is used in the CC. GTDS was
developed with funding support by the Federal Ministry of Health
of Germany in the early 1990s. It is used in about 60 cancer
registries and is updated regularly to meet new standards and
requirements [23]. GTDS is managed via a graphical user interface
which is used in daily routine at the CC or for simple analyses. For
more complex reports or record exports, a command-line interface
is available. Both ambulatory and stationary follow-up assign-
ments are recorded in the GTDS-system.
3.2. Model generation process
We defined a process to generate a Markov model what we
refer to as ‘semi-automatically’, see Fig. 1. In this context, semi-
automatically means that the selection of meaningful clinical
parameters is done manually, see Step 1. All other steps in the
generation process are performed automatically, e.g., generation
of database queries or probability calculations. A detailed descrip-
tion of the process is given in the subsequent sections The model
generation software was developed in Java to support the process
and to visualize the results.
3.2.1. Step 1 – definition
At first, the disease states of the Markov model have to be
defined. This is based on physiological knowledge about the dis-
ease, its progression and best practices. In order to use a database
for the generation of a Markov model structure, the medical defini-
tion of a state hast to be mapped to database columns and their
specific values. An example for such a mapping can be found in
Table 2.
It is mandatory to confer with physicians, documentation
officers, study nurses, etc., to obtain the best mapping between
medical state description and database structure.
3.2.2. Step 2 – selection
The result of Step 1, i.e., the previously defined disease state
mapping, is used to automatically generate SQL (Structured Query
Language) statements to query the related dataset. Each disease
state is reflected in one specific SQL statement. If a patient is
selected by a query, the related patient record applies to the asso-
ciated disease state. Only those selected patients are considered in
Step 3 and Step 4. Patients can be matched to [1. . .n] states, which
reflect the progression of the disease over time. For example, if a
patient is declared as disease free, he/she may have a relapse and
may die after another five years. This procedure would then yield
three matching disease states (Disease free – Recurrence – Death)
for this particular patient.
3.2.3. Step 3 – transformation
Selected patients from Step 2 and their associated [1. . .n] dis-
ease states are sorted by the date of the observation. This way, a
sequence of events is derived for every patient. Usually these
events are scattered over the entire time horizon H of the model
Fig. 1. Model generation process: Illustration of the proposed 4-step model generation process.
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time gaps using the last observation carried forward method
(LOCF), see Fig. 2.
At the end of Step 3, every patient has a complete disease state
sequence which spans H, as previously defined for that particular
data analysis.
3.2.4. Step 4 – generation
A model structure consists of S states and n2 transitions. A
change of a state in the patient’s sequence indicates such a transi-
tion. Patients’ shifts between states can be denoted as a transition
count matrix Uct , see Eq. (1). A shift represents a change from state
si into a subsequent state sj.
Uct ¼
u11 u12 . . . u1n
u21 u22 . . . u1n
..
. ..
. . .
.
. . .
un1 un2 . . . unn
0
BBBB@
1
CCCCA
i ¼ f1; . . . ;ng; j ¼ f1; . . . ;ng ð1Þ
For instance, u12 represents the number of patients which shift
from the disease state s1 to s2. Accordingly, patients that transit
from a later disease state s2 to an ‘‘earlier” state s1 are given by
u21. Hence, according to [24], the maximum likelihood estimate of
the transition matrix for the probability of any shift equals the
row proportions of Uct given by Eq. (2).Fig. 2. Sequence transformation: An example for the transformation process of a sequ
sequence represents the expanded first sequence. The patient remains in the state ‘‘DisePsisj ðctÞ ¼
uijPn
r¼0uir
ð2Þ
Based on the data of Step 3, the detected transitions determine a
model structure which contains health states and transitions
between them.3.2.5. Export and optimization
Our software allows the export of the suggested model struc-
ture in a spreadsheet file format. We chose this file format as it
supports further parametrization of a DM without restriction to a
dedicated simulation and modeling software like TreeAge or Arena.
In addition, spreadsheet programs like Microsoft Excel are consid-
ered capable enough for all aspects of Markov model generation
and result presentation [20].
Further allocation of parameters such as costs and utilities or
the optimization and fitting of transition probabilities could be
necessary if a model should be used in a health economic
evaluation.3.3. Reference model
We rely on the Markov model for breast cancer relapse and sur-
vival which was published by Blank et al. [3] as a reference for our
validation study, see Section 4. We chose it because it reflects aence. The first sequence has two states and a time gap of four years. The second
ase free” for four cycles (LOCF).
388 M. Pobiruchin et al. / Journal of Biomedical Informatics 60 (2016) 385–394European healthcare setting and uses data from the important and
well accepted European HERA trial [15].
HERA was an international, intergroup, open-label, phase III
randomized trial involving women with HER2-positive early-
stage invasive breast cancer. One study group in HERA was treated
with Trastuzumab for two years. Another group only received
Trastuzumab for one year. HERA showed that women with
HER2-positive breast cancer can benefit from Trastuzumab. The
rate of recurrence, particularly distant recurrence, was reduced by
approximately 50%. However, it increases treatment costs drasti-
cally. In 2006, Trastuzumab was approved for adjuvant chemother-
apy for breast cancer patients. In 2008, the updated version of the
German clinical guideline for breast cancer recommended the
usage of Trastuzumab [25].
The structure of the model by Blank et al. is similar to other
health economic evaluations regarding breast cancer and its recur-
rence [6]. Other DMs, for example Braun et al. [26] or Bos et al. [27],
use additional information on menopausal status and nutrition.
However, such parameters are not documented in our clinical
dataset and therefore those DMs are not suitable for comparison
in our setting.
The DM by Blank et al. defines disease states as Disease free,
Local recurrence, Regional recurrence, Metastasis, and Death with
possible transitions between these states as illustrated in Fig. 3.
Blank et al. uses the data from the HERA-trial [15] to model
disease-free survival of HER2-positive/-negative patients. Probabil-
ities for recurrences were derived from published retrospective
reviews of medical records and not dependent on HER2-status
[28,29]. Survival rates for metastatic breast cancer patients origi-
nate from two phase III trials [30,31]. The authors assume that
after five years, the risk of reappearing metastasis would decline
by 10% annually [32]. They create a life-long Markov model with
a time horizon of H = 50 years and a cycle length of ct = 1 year.4. Validation study
4.1. Patient cohort and characteristics
The data protection officer of the SLK-Hospital Holding was
involved in the early phase of our study to ensure compliance to
German privacy legislation. Furthermore, the project was evalu-
ated and approved beforehand by the Ethics Committee of the
Medical Faculty of the University of Heidelberg.
A de-identified copy of the GTDS system was created and pro-
vided by the CC. In 2004, the CC was certified as specialized center
for breast cancer by the German Cancer Society. An almostFig. 3. Model Structure: Structure and transitions between disease states according
to Blank et al. [3].complete and valid documentation of patient records can be
assumed since this year. Relapses often occur one to two years
after initial primary treatment. Therefore, we only considered
female breast cancer patients which were diagnosed from 01-01-
2004 to 31-12-2012 (n = 3230) as patients diagnosed in the subse-
quent years might not have developed a relapse yet. Accordingly,
the time horizon of our model study was set to H = 8 years.
Records were checked for duplicates or implausible entries, e.g.,
date of death prior to date of being disease free. Entries for TNM
Classification of Malignant Tumors (TNM) and grading of tumors
were cleaned to ensure comparability. For instance, in some cases
grading was documented as ‘G2’ instead of ‘2’, TNM-stages were
reduced to the major groups ‘1’, ‘2’, ‘3’ and ‘4’ instead of ‘1a’ for
example.
We identified and applied mutual inclusion criteria as shown in
Fig. 4 compatible to our clinical reference study [15]. A main issue
was the correct identification of HER2-positive women. As cut-off
for HER2-positivity we chose values of ‘2’ and ‘3’ in the recorded
results of immunohistochemistry (IHC) examinations.
According to the German clinical guideline for breast cancer,
HER2-positive patients can be treated with either Trastuzumab
(trade name: Herceptin) or Lapatinib (trade name: Tykerb/Tyverb)
[25]. Patients which received such a treatment were identified via
a search for systemic therapy protocols that contained the terms
‘Trastuzumab’, ‘Herceptin’ or ‘Lapatinib’. The query results showed
that Lapatinib-treatment was documented for only one patient.
The related record was not considered for further analysis as it is
not relevant for the generation of a Trastuzumab-related DM.
In total, four separate patient cohorts were identified from the
remaining records (n = 892):
C-1. Patients with positive HER2 status and no Trastuzumab
treatment (n = 145)
C-2. Patients with positive HER2 status and with Trastuzumab
treatment (n = 138)
C-3. Patients with negative HER2 status and no Trastuzumab
treatment (n = 606)
C-4. Patients with negative HER2 status and with Trastuzumab
treatment (n = 3)
As the modeling study of Blank et al. [3] created a DM for every
cohort, we first intended to compare the related structure and
transition probabilities with the cohorts as found in our data. How-
ever, cohort C-4 needed to be excluded, since from a clinical point
of view it is not appropriate to treat HER2-negative patients with
Trastuzumab. We assume that there are either misclassifications
or documentation errors in these three records. Unfortunately,
we could not further investigate on these issues as we had no
access to the original records and/or hospital-wide information
system.
A first patient characteristics analysis of the cohorts C-1 to C-3
revealed that there were differences with respect to the distribu-
tion of age, tumor sizes, hormone receptor status, etc. Therefore,
we balanced cohorts C-1 to C-3 with the propensity score matching
method [33]. For this step, we used the MatchIt-package for the
statistical software R which implements the nearest neighbor
method [34]. Cohort C-2 served as reference population for the
matching process.
Some of the HERA-trial baseline characteristics were not docu-
mented at all in the GTDS-system, e.g., race of the patients, meno-
pausal status. Thus, not every variable could be considered and we
only used a subset (6 out of 13) of the HERA baseline characteris-
tics, see Table 1.
Information on the other seven criteria is provided as additional
Supplementary material in Appendix A.
Fig. 4. Inclusion and exclusion criteria: Inclusion and exclusion criteria of the patient cohort according to the HERA-trial [15].
M. Pobiruchin et al. / Journal of Biomedical Informatics 60 (2016) 385–394 389Based on the model developed by Blank et al., we tried to map
the given description for every disease state to columns docu-
mented in the GTDS dataset. A closer examination of the dataset
revealed that no differentiation between local and regional recur-
rence was made for most records. Therefore, only one state of
Recurrence instead of two states (Local recurrence and Regional
recurrence) exists.
Patients do not transit to the state Disease free once a recurrence
or metastasis has occurred. In our model structure, every disease
state is associated to only one specific calendar date. As a conse-
quence, we introduced separate remission-states to allow patients
to recover from their recurrence or metastases. The adapted model
structure is depicted in Fig. 5. A detailed description of the final
mapping between disease states and columns in GTDS is described
in Table 2.
4.2. Model assumptions
The generated DM’s structure and its transitions probabilities
depend on the underlying real-world dataset. We generated the
model under the following assumptions:HER2-positivity is assumed if the result of the IHC test is reported
as ‘2’ or ‘3’. Patients with an intermediate score of ‘2’ are often addi-
tionally tested with Fluorescence in situ Hybridization (FISH) to con-
firm their HER2-status. However, and in accordance to the model
developed by Blank et al. [3] we choose IHC testing only.
A clear differentiation between a recurrence and a metastatic
relapse can be made and can be detected in the dataset.
Relapses or deaths do not take place within twelve months after
the initial tumor treatment. Therefore, we define a cycle length of
one year, i.e., ct = 1
Trastuzumab treatment is conducted in accordance to good
clinical practice. If a Trastuzumab treatment is detected in the
related patient entry, the treatment procedure is considered to
be successfully completed and that no side effects or adverse
events occurred.
4.3. Statistics
For a statistical comparison between the cohorts, we decided
to compare cohort C-1 to C-2, i.e., treatment with/without
Trastuzumab for HER2-positive women. After 8 years we counted
Table 1
Baseline characteristics of patients, tumors, and primary treatments in the CC dataset.
ER: Estrogen-receptor. PR: Progesterone-receptor.
Variable HER2+/
Trastuzumab
HER2+/No
Trastuzumab
HER2-/No
Trastuzumab
Age – No. (%)
<35 years 1 (0.7) 1 (0.7) 3 (2.2)
35-49 years 50 (36.2) 47 (34.1) 40 (29.0)
50-59 years 33 (23.9) 39 (28.3) 31 (22.5)
>= 60 years 54 (39.1) 51 (37.0) 64 (46.4)
Nodal status – No. (%)
Not assessed (neoadjuvant
chemotherapy)
30 (21.7) 21 (15.2) 13 (9.4)
Negative 48 (34.8) 53 (38.4) 43 (31.2)
1-3 Positive nodes 35 (25.4) 42 (30.4) 50 (36.2)
>= 4 Positive nodes 24 (17.4) 23 (16.7) 32 (23.2)
Missing 1 (0.7) 0 (0.0) 0 (0.0)
Pathological tumor size – No. (%)
Not assessed (neoadjuvant
chemotherapy)
30 (21.7) 21 (15.2) 13 (9.4)
in situ 1 (0.7) 0 (0.0) 0 (0.0)
0–2 cm 45 (32.6) 37 (26.8) 46 (33.3)
>2–5 cm 53 (38.4) 67 (48.6) 67 (48.6)
>5 cm 4 (2.9) 8 (5.8) 10 (7.2)
Any size with direct
extension to chest wall or
skin
5 (3.6) 4 (2.9) 2 (1.4)
Missing 0 (0.0) 1 (0.7) 0 (0.0)
Hormone-receptor status – No. (%)
ER-negative and PR-negative 64 (46.3) 24 (17.4) 37 (26.8)
ER-negative and PR-positive 1 (0.7) 1 (0.7) 0 (0.0)
ER-negative and PR-
unknown
0 (0.0) 0 (0.0) 0 (0.0)
ER-positive and PR-positive 50 (36.2) 91 (65.9) 80 (58.0)
ER-positive and PR-negative 13 (9.4) 17 (12.3) 17 (12.3)
ER-positive and PR-unknown 0 (0.0) 0 (0.0) 1 (0.7)
ER-unknown and PR-positive 0 (0.0) 0 (0.0) 0 (0.0)
Missing 10 (7.2) 5 (3.6) 3 (2.2)
Histologic grade of tumor – No. (%)
3 (Poorly differentiated) 84 (60.9) 59 (42.8) 51 (37.0)
2 (Moderately differentiated) 45 (32.6) 69 (50.0) 70 (50.7)
1 (Well differentiated) 2 (1.4) 5 (3.6) 7 (5.1)
Not assessed 0 (0.0) 0 (0.0) 0 (0.0)
Missing 7 (5.1) 5 (3.6) 10 (7.2)
Previous radiotherapy – No. (%)
Yes 112 (81.2) 120 (87.0) 117 (84.8)
No 26 (18.8) 18 (13.0) 21 (15.2)
Fig. 5. Generated models: Common model structure and transitions of the
generated models.
Table 2
Disease states mapping as used in the generated DM according to [3]. K = no evidence
(German: Kein Befund). V = full remission (German: Vollremission), M = existing
metastases, R = new metastases, B = existing or new metastases.
Name of
disease state
Column name/value Description
Disease free DISEASEFREE_DATE= any
date
Date of being declared disease
free for the first time
DATA_TYPE = Diagnosis Surrogate value indicating if
the entry is associated with
the first diagnosis
Recurrence RECURRENCE_DATE = any
date
Date of first recurrence
Metastasis METASTASIS_DATE = any
date
Date of first metastasis
METASTASIS = M or R or B An entry in this column
indicates a metastatic relapse
Remission
recurrence /
Remission
metastasis
REMISSION_DATE= any
date
Date in the record after
patient was declared disease
free for the 2nd time after a
recurrence / metastasis
DATA_TYPE = Progress Surrogate value: if the patient
record is associated with
progress information
originating from follow-up
care
PRIMARYTUMOR = K Progress record of the patient,
no evidence of primary tumor
was found
METASTASIS = K Progress record of the patient,
no evidence of any metastases
was found
OVERALLASSESSMENT = V Final assessment of the
390 M. Pobiruchin et al. / Journal of Biomedical Informatics 60 (2016) 385–394the number of patients still being disease free, having a relapse or
metastases. We performed the exact binomial test with the pro-
portions of cohort C-1 as the probability of success. Proportions
of C-2 for being disease free after 8 years were expected to be
greater than in C-1. Proportions for a relapse were expected to be
less than in C-1 (one-sided test, alpha error 0.05).patient with a full remission
of the tumor
Death DEATH_DATE = any date Date of death, converted to
mid of month5. Results
To obtain real world driven DMs for our setting, we derived the
structure and the transition probabilities according to the process,
defined in Section 3. As outlined in Section 4.1 three models – each
for every patient cohort – were generated.
The common structure of each model is illustrated in Fig. 5. The
disease states are Disease free, Recurrence, Remission recurrence,
Metastasis, Remission metastasis, and Death. At cycle c0, virtually
all women are assumed to be Disease free.
Afterwards patients may progress to the states Recurrence,
Metastasis or Death. As depicted, patients do not transit into the
state Disease free after a recurrence.
Our findings confirm the positive effect of Trastuzumab treat-
ment in HER2-positive women in routine care. The probabilitiesto remain Disease free are significantly higher (p = 0.04) in that
cohort compared to HER2-positive women who were not treated
with Trastuzumab, and the probabilities for a relapse are smaller
for patients in that cohort too, see Table 3.
We found that in the C-2 cohort 97.8% of the patients are still
alive after 24 months, in comparison to 95.7% in the C-1 cohort.
In the HERA-study 96% (Trastuzumab-arm) and 95.1% (observation
arm) were still alive after 24 months, respectively. In the model’s
C-2 cohort, 93.8% of the patient survived free of disease after
24 months (85.8% in HERA). In the C-1 cohort, 86.0% survived
disease free (77.4% in HERA).
Table 3
Annual transition probabilities generated for the CC dataset and the number of transitions observed in the dataset. Note: Only three of all (14) transition matrices are shown here.
Values given by Blank et al. [3] are shown in (). P-Values report the results from the statistical comparison between C-1 and C-2. For all calculated transition probabilities see
Table 1 in [35].
Cycle ct 1 2 3 4 5 6 7 8 p-Value
Disease free? Disease free
C-1:HER2+/No Trastuzumab 92.6 92.9 94.9 99.1 100 99.1 100 96.3 0.04
126 117 111 110 110 109 109 105
(87.9)
C-2: HER2+/Trastuzumab 96.1 97.6 97.5 99.2 98.3 100 100 99.1
124 121 118 117 115 115 115 114
(93.4)
C-3:HER2-/No Trastuzumab 93.4 97.6 94.4 100 98.3 97.4 98.2 99.1
127 124 117 117 115 112 110 109
(97.5)
Disease free? Recurrence
C-1:HER2+/No Trastuzumab 2.2 1.6 0.9 0.9 0.0 0.9 0.0 0.9 ns
3 2 1 1 0 1 0 1
(3.0)
C-2: HER2+/Trastuzumab 2.3 0.0 2.5 0.0 0.9 0.0 0.0 0.9
3 0 3 0 1 0 0 1
(1.6)
C-3:HER2-/No Trastuzumab 1.5 0.8 1.6 0.0 0.0 1.7 1.8 0.0
2 1 2 0 0 2 2 0
(0.8)
Disease free?Metastasis
C-1:HER2+/No Trastuzumab 4.4 4.0 3.4 0.0 0.0 0.0 0.0 2.8 <0.01
6 5 4 0 0 0 0 3
(9.1) (8.2) (7.4) (6.6)
C-2: HER2+/Trastuzumab 0.8 1.6 0.0 0.0 0.8 0.0 0.0 0.0
1 2 0 0 1 0 0 0
(5.0) (4.5) (4.1) (3.6)
C-3:HER2-/No Trastuzumab 3.7 1.6 1.6 0.0 0.9 0.9 0.0 0.0
5 2 2 0 1 1 0 0
(1.7) (1.5) (1.4) (1.2)
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In this article we presented an approach to generate DMs based
on routine care data documented in a clinical cancer registry. The
semi-automatic generation of such DMs is shown as feasible and
the generated results are comparable to a reference model.
Similar to our approach work by Abler et al. describes a disease
modeling process [36]. They present a ‘‘data-driven Markov model”
in the evaluation of adverse events in a radiotherapy setting. In
their approach, they first create a meta-language to describe health
states and their transitions. Next, a generated template is used to
derive Markov models from distinct data sources. Finally, they
demonstrate their method with an artificially generated toxicity
dataset.
Another investigation in this field was conducted by Lange et al.
[37]. In their work, they developed a ‘‘joint model” of a discretely
observed ‘‘multistate disease process” and a random observation
time process. For illustration purposes, they apply this model to
a secondary breast cancer event study. Thereby, they utilize mam-
mography and biopsy records from a sample of female primary
breast cancer patients. As a result, prevalence information of unde-
tected secondary breast cancer events is computed via the gener-
ated model.
In comparison to these two approaches, real world data is also
increasingly used in modeling and health services research: Erenay
et al. [38] used a clinical database to analyze 284 patients with col-
orectal cancer. They calibrated a discrete event simulation with
real world clinical data manually extracted from a free text
surgery-centric database. Their simulation outcomes supported
the understanding of progression and characteristics of metachro-
nous colorectal cancer.
The authors of [39] estimated transition probabilities for kidney
disease with Hidden Markov Models trained on data from a state-wide health care provider in the USA. The patient cohort comprised
about 60,000 cases and allowed for insights in the progression of
chronic kidney disease states.
Health care data is also frequently used in the field of predictive
modeling: For instance prediction of outcomes of pneumonia
patients [40], finding associations between medication, laboratory
result and patients’ problem lists [41] or providing decision sup-
port in pediatrics [42].
In this context, national standardization and initiatives could be
a way to enable more researchers to work with real world clinical
data. In the US, the Observational Medical Outcomes Partnership
(OMOP) utilized several heterogeneous data sources to combine
them via a common data model in order to monitor medical prod-
ucts safety [43]. However, common data models in the US have
not been widely adopted either. OMOP (and most other models)
tend to be utilized only for specific, time-limited, grant-funded
research networks.
Even though data on cancer is documented in registries since
1920 in Germany [44], no general consensus between health care
providers, institutions and different federal state laws [45] in terms
of harmonized data models and crosslinks between data sources
exists [23]. As a consequence, it is difficult to apply such a common
data model to this ‘‘uncoordinated patchwork” and Germany’s
‘‘unique structural problems” [45].
In general, our work contributes to all those approaches that
leverage routine care data for model generation and calibration.
But there are two aspects in which our work is different: Authors
of [38,39] used routine care data to gain insights in a partially
unknown disease process. Such insights could be used for the cal-
ibration of predictive models later. Compared to these approaches,
we intend to use the generated models’ structures and transition
probabilities for another field of usage: Health services research
and health economics. For that reason we also applied a methodol-
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research [20].
Moreover, we used data directly taken from a tumor documen-
tation database, i.e., it does not originate from a generated dataset
or idealized study setting (compared to [36,37]). In contrast to [38],
our approach relies directly on an established and well
documented system – the GTDS – which is compliant with national
cancer data set regulations in Germany. Therefore, our system can
leverage newly documented tumor cases via a quick database syn-
chronization with the underlying documentation system. This
reduces the burden of manual free text extraction and allows for
rapid model recomputation.
Despite using real world data, our validation phase’s results
could confirm the positive effects of Trastuzumab in treating breast
cancer. This is in accordance to findings by Benson and Hartz [46]
who could show in a meta-analysis of 136 reports that treatment
effects of observational studies compared to RCTs are not ‘‘consis-
tently larger or qualitatively different”. Furthermore, this work is
the first contribution of clinical cancer registry data utilization
for Markov model generation based on a GTDS data source in
Germany.
6.1. Data source
Population-based cancer registries collect data on all new cases
observed in a well-defined population, e.g., a federal state. Such
data sources are essential for epidemiology research and public
health in general. In contrast, clinical cancer registries document
treatment-related information on cancer patients, including, e.g.,
surgery, radiotherapy, and chemotherapy data. Clinical cancer reg-
istries are often hospital- or institution-based. Their records are
mainly used for administrative purposes and providing data for
population-based cancer registries [47]. Because of the holistic
and more extensive documentation of treatment processes and
interdisciplinary data, clinical cancer registries like the CC
Heilbronn-Franken are an adequate basis for studies in the field
of health services research [48].
Usage of data from routine care poses new limitations and pit-
falls in terms of data quality. We found that local documentation
practice does not always clearly differentiate between metastases
and local/regional recurrences in the records. For this reason, the
probabilities to get a metastasis might be underestimated, whereas
the recurrence probability might be slightly overestimated.
Follow-up care of breast cancer patients is triggered by symp-
toms [25]. There is no strict follow-up scheme in the German treat-
ment guidelines as it is found for example in the treatment
guidance for colon cancer that binds patients to their initial treat-
ment hospital. Therefore, some relapse events might not be cap-
tured in our dataset because they were not treated by SLK. We
had no information whatsoever to quantify this bias.
Legal privacy restrictions prevented a source data verification
[49] and comparison of the documented data with the potential
drop-out records in our de-identified database. Hence, such docu-
mentation faults could not be resolved. This obstacle affected only
five patient records and can be considered negligible.
Not each baseline characteristic of the patient cohorts defined
in [15] could be used to balance our cohorts. This limitation origi-
nates from the fact that some variables in our records were not
documented at all, e.g., ethnicity of the patients. Some others were
only available as semi-structured free text, e.g., dosing information
of adjuvant chemotherapy. Therefore, we assumed that all patients
with at least one Trastuzumab data entry were treated according to
best practice and no adverse events or interruption had occurred.
However, these assumptions might increase the number of women
who received Trastuzumab in the model. Therefore one could
expect false high rates for survival and disease free time periods.In fact, our model reports higher survival rates (max. 2%) and
higher disease free proportions (max. 8%) compared to the HERA
results. We were not able to quantify the effect of treatment qual-
ity or guideline adherence. This aspect might be considered in
future research when more detailed and structured patient data
should be available.
Sparse data is a crucial limitation for our approach. If small
patient cohorts are leveraged as a basis for probability calculations,
the calculated outputs could be biased. Access to additional GTDS
tumor documentation systems from other clinical cancer registries
could increase the sample size and generate more precise models.
This particular aspect is of importance to real world data driven
DM as patient cohorts in RCTs are typically less diverse with regard
to age, quality of life and comorbidities than in the health care
system. RCT driven DM need smaller sample sizes to demonstrate
significantly different outcomes.
By principle, regional data make ‘regional models’. Other regio-
nal data might reflect different medical treatment procedures. In
order to raise the representativeness of models derived by our
methodology one would like to pool comparative data from multi-
ple cancer centers. In our study such additional databases were not
available. Therefore the representativeness of our modeling results
remains open. However, regional models allows for regional clini-
cal profiles which could give physicians information about their
respective treatment patterns and compare them with those of
other physicians, wards, hospitals, etc. [50].
Pre-processing and validation of cancer records are laborious
and challenging tasks before the data can be used for the computa-
tion of a DM. Typical documentation errors made in a particular
institution which might differ from errors in other institutions
are unknown. Therefore, the plausibility of patient data can only
be judged if knowledge on the local documentation process is
available and pre-studies are conducted. However, we previously
investigated together with the SLK documentation team on the
data quality of the breast cancer records in the CC in terms of com-
pleteness, correctness, timeliness and validity. Our independently
published results show that the data quality is predominantly good
in terms of completeness and correctness [51].
Due to the working routines in the CC cancer patients’ records
are not automatically transferred from the hospital-wide informa-
tion system into the GTDS. In fact, this step is mostly done manu-
ally by medical documentation specialists. This could pose an error
source of its own.
6.2. Model characteristics
There are some differences between our generated DM and the
Blank et al. model [3] in terms of structure and probabilities: In our
model, patients can shift to the state Death at any time. This is in
contrast to the literature model where patients only shift to the
Death-state if they were previously associated to the Metastasis-
state. Most of the annual transition probabilities in the other model
remain stable throughout the whole time horizon of H = 50 years,
whereas the probabilities in our model change every year. This is
due to the computation process of the transition probabilities
which depends on uij from the maximum likelihood estimator,
see Eq. (2) as uij changes depending on the disease state and cycle
ct. Table 3 shows the differences between the probabilities pub-
lished by Blank et al. compared to our calculated transition proba-
bilities. Larger differences were observed in particular for the
probabilities for a metastatic relapse.
The probabilities of remaining Disease free or suffering from a
Recurrence computed with our DM are gradually declining in con-
trast to remaining stable as in the model by Blank et al. There is
general consensus that the risk of recurrence is higher in the first
two years after initial treatment of the primary tumor and declines
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transition probabilities.
The estimated transition probabilities in our DM were not age-
dependent because the whole patient cohort was used for the gen-
eration process. Most decision models are based on age-dependent
transition probabilities, though. Our proposed process is able to
calculate age-dependent transition probabilities given the data
source is big enough. Patient cohorts could be split into desired
age groups. The generation algorithm could then be performed
with this sub-cohort. However, sub-cohorts may be too small in
terms of sample size to achieve reliable results.
An integration of other clinical data sources such as billing infor-
mation, secondary diseases, and length of hospital stays could pro-
vide additional insight to the added values of therapies. Cost data
were completely disregarded in this modeling study due to privacy
reasons which restricted access to accounting data of the SLK hos-
pital information system. The GTDS-system documents only
treatment-related data. However, our software allows the export
of results to a spreadsheet software. One could then manually allo-
cate costs and utility values to the proposed health states. Further-
more, optimization and fitting of the calculated probabilities could
be performed. This way, additional data sources could be consid-
ered in the computed results like overall mortality obtained from
national registries or data from RCTs if certain aspects are not cov-
ered in the locally documented data. Nevertheless, adequate prepa-
ration and inclusion of heterogeneous information like RCT, expert
option, etc., into one particular model structure is cumbersome and
may post a source of bias, see e.g., [53].
A further development of our model generation algorithm
includes the usage of cluster analysis techniques to identify mean-
ingful medical parameter combinations [54]. Such combinations
could identify previously unknown disease states. Thus, new
models might be found without relying on existing literature and
cost-intensive studies. This approach would then represent a ‘fully
automatic’ method.
7. Conclusion
In this article, we outlined a feasible approach to generate
Markov based DMs on real world data of a regional clinical cancer reg-
istry. A generic process for such a model generation is presented.
To evaluate the formal correctness, it was compared to a published
Markov DM by Blank et al. [3]. Our generated DM’s structure was
similar to the one described there. Comparable transition probabil-
ities were computed for disease free survival. In terms of recur-
rence and metastasis remission probabilities, our DM differs from
the model used for comparison as discussed in Section 6. However,
the results from our validation study confirm the expected positive
effect of Trastuzumab treatment in HER2-positive women for a
routine care setting in Germany.
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